SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bafna Pharmaceuticals informs about outcome of board meeting

12 Sep 2017 Evaluate

Bafna Pharmaceuticals has informed that the board of directors of the company, at its meeting held on 8th day of August, 2017 has considered and approved the Directors report; fixed date, place, and time of 22nd AGM; fixed Book Closure for 22nd AGM; fixed Cut-off Date for voting; to recommend the appointment of Statutory Auditor of the Company; to recommend the re-appointment of Managing Director of the Company; and to recommend the re-appoint of Whole time Director of the Company.

The above information is a part of company’s filings submitted to BSE.

Bafna Pharma Share Price

145.00 12.40 (9.35%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×